Abstract
Candida auris is a rapidly emerging multidrug-resistant pathogenic yeast. In recent years, an increasing number of C. auris invasive infections and colonized patients have been reported, and C. auris has been associated with hospital outbreaks worldwide, mainly in intensive care units (ICUs). Here, we describe the first two cases of C. auris in The Netherlands. Both cases were treated in a healthcare facility in India prior to admission. The patients were routinely placed in contact precautions in a single room after admission, which is common practice in The Netherlands for patients with hospitalization outside The Netherlands. No transmission of C. auris was noticed in both hospitals. Routine admission screening both for multidrug-resistant (MDR) bacteria and MDR yeasts should be considered for patients admitted from foreign hospitals or countries with reported C. auris transmission.
Highlights
Since the first report of Candida auris in 2009, an increasing number of C. auris invasive infections and colonized patients have been reported in at least 37 countries and territories, including the USA, Africa, Europe, and Asia [1,2,3,4,5,6,7,8]
Broth microdilution showed that both C. auris isolates had high fluconazole (>64 mg/L) and voriconazole (4 mg/L) minimum inhibitory concentrations
Molecular typing with amplified fragment length polymorphism and microsatellite concentrations (MICs)
Summary
Since the first report of Candida auris in 2009, an increasing number of C. auris invasive infections and colonized patients have been reported in at least 37 countries and territories, including the USA, Africa, Europe, and Asia [1,2,3,4,5,6,7,8]. C. auris has been associated with outbreaks in hospitals and other healthcare facilities. Ongoing transmission despite enhanced infection prevention and control measures during nosocomial outbreaks has been reported in several studies [4,5]. Resistance of C. auris to several antifungal classes of drugs with few having high minimum inhibitory concentrations (MICs) to all major drug classes has been described [9,10,11]. The nosocomial outbreaks and multidrug resistance of C. auris are worrisome and call for enhanced hospital infection prevention measures [12,13].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
